Shattuck Labs

Takeda, Shattuck Labs partner on immuno-oncology

Monday, August 14, 2017

Takeda Pharmaceutical and Shattuck Labs have entered into a research collaboration to explore and develop checkpoint fusion proteins that have the potential to become highly differentiated, next-generation immunotherapies. Under the terms of the collaboration agreement, Takeda will hold options for exclusive global development and commercialization rights for up to four molecules resulting from the collaboration.

[Read More]